iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
P/E ratio for iRhythm Technologies, Inc. (IRTC)
P/E ratio as of 2023: -26.48
According to iRhythm Technologies, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -26.48. At the end of 2022 the company had a P/E ratio of -24.12.
P/E ratio history for iRhythm Technologies, Inc. from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -26.48 |
| 2022 | -24.12 |
| 2021 | -34.06 |
| 2020 | -150.21 |
| 2019 | -31.53 |
| 2018 | -34.37 |
| 2017 | -43.11 |
| 2016 | -7.59 |
| 2015 | -16.87 |
| 2014 | -24.30 |
| 2013 | -2.44 |